Summary
The Zucker fatty rat (fa/fa; ZR) is considered as a model for pre-diabetes, as characterised by a genetic defect in the leptin receptor, which results in hyperphagia, insulin resistance, hyperinsulinaemia, hyperlipoproteinaemia, and obesity. These animals become glucose intolerant but do not develop type 2 diabetes. As a consequence of increased adiposity and insulin resistance, the endocrine pancreas of ZR undergoes adaptive and compensatory changes. Measurements of the time course of the pathological changes by the histological analysis of the pancreatic islet in combination with metabolic parameters are an effective way to reveal disease progression. A loss in glucose tolerance occurs in ZR by 10 weeks of age and progressively worsens by 19 weeks of age. This process is accompanied by impaired islet histology, changes of β-cell mass, and impaired islet function. The early expression of insulin resistance and glucose intolerance in ZR results in morphological and functional changes of pancreatic islets despite their capability to maintain normoglycaemia.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Weir G. C., Laybutt D. R., Kaneto H., Bonner-Weir S., and Sharma A. (2001). Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes 50 Suppl 1, S154–S159
Beck-Nielsen H. and Groop L. (1994). Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J. Clin. Invest.94, 1714–1721
Ferrannini E. (1998). Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr. Rev 19, 477–490
Ritzel R. A., Butler A. E., Rizza R. A., Veldhuis J. D., and Butler P. C. (2006). Relationship between β-cell mass and fasting blood glucose concentration in humans. Diabetes Care 29, 717–718
Clark A., Jones L., de Koning E., Hansen B. C., and Matthews D. R. (2001). Decreased insulin secretion in type 2 diabetes: a problem of cellular mass or function? Diabetes 50, S169–S171
Chan C. B., Wright G. M., Wadowska D. W., MacPhail R. M., Ireland W. P., and Sulston K. W. (1998). Ultrastructural and secretory heterogeneity of fa/fa (Zucker) rat islets. Mol. Cell Endocrinol. 136, 119–129
Finegood D. T., McArthur M. D., Kojwang D., Thomas M. J., Topp B. G., Leonard T. et al (2001). Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 50, 1021–1029
Tikellis C., Wookey P. J., Candido R., Andrikopoulos S., Thomas M. C., and Cooper M. E. (2004). Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. Diabetes 53, 989–997
Schröder D., Berg S., Altmann S., Lucke S., Augstein P., and Salzsieder E. (2006). Charakterisierung von Zucker fatty Ratten (fa/fa) - Beziehung von Stoffwechselparametern, Glukosetoleranz und Eigenschaften isolierter Langerhansscher Inseln. Diabetologie und Stoffwechsel 1, 64–A-132
Berthiaume N., Mika A. K., and Zinker B. A. (2003). Development of insulin resistance and endothelin-1 levels in the Zucker fatty rat. Metab. Clin. Exp. 52, 845–849
Apweiler R. and Freud P. (1993). Development of glucose intolerance in obese (fa/fa) Zucker rats. Horm. Metab. Res. 25, 521–524
Wargent E., Stocker C., Augstein P., Heinke P., Meyer A., Hoffmann T. et al (2005). Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone. Diabetes Obes. Metab. 7, 170–181
Buckingham R. E., al Barazanji K. A., Toseland C. D., Slaughter M., Connor S. C., West A. et al (1998). Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 47, 1326–1334
Augstein P., Schlosser M., Ziegler B., Hahmann J., Mauch L., and Ziegler M. (1996). Comparison of the islet cell antibody pattern of monoclonal glutamic acid decarboxylase antibodies recognizing linear and conformational epitopes. Acta Histochem. 98, 229–241
Augstein P., Elefanty A. G., Allison J., and Harrison L. C. (1998). Apoptosis and beta-cell destruction in pancreatic islets of NOD mice with spontaneous and cyclophosphamide-accelerated diabetes. Diabetologia 41, 1381–1388
Romeis. Mikroskopische Technik. (17th ed) (1989). München; Wien; Baltimore: Urban ‘ Schwarzenberg
Hofman F. (2002). Immunohistochemistry. In: Current Protocols in Immunology. John Wiley & Sons, Inc., New York, 21.4.1–21.4.23
Augstein P., Braun B., Ziegler B., Woltanski K. P., and Ziegler M. (1992). Characterization of two porcine proinsulin reactive monoclonal antibodies by immunostaining of beta-cells in pancreatic sections of different species. Acta Histochem. 93, 433–440
Witt S., Dietz H., Ziegler B., Keilacker H., and Ziegler M. (1988). Production and use of monoclonal glucagon and insulin antibodies - reduction of pancreatic insulin in rats by treatment with complete Freund’s adjuvant. Acta Histochem. Suppl 35, 217–223
Hahn H. J., Gerdes J., Lucke S., Liepe L., Kauert C., Volk H. D. et al (1988). Phenotypical characterization of the cells invading pancreatic islets of diabetic BB/OK rats: effect of interleukin 2 receptor-targeted immunotherapy. Eur. J. Immunol. 18, 2037–2042
Lucke S., Ziegler B., Weidlich K., Barowski U., Besch W., and Hahn H. J. (1985). The effects of subdiabetogenic streptozotocin doses on rat beta cell volume and functions. Biomed. Biochim. Acta 44, 167–171
Weibel E. R. (1969). Stereological principles for morphometry in electron microscopic cytology. Int. Rev. Cytol. 26, 235–302
Lucke S. (1987) Die Bedeutung der reduzierten β-Zellmasse für die Regeneration der insulinproduzierenden Zellen im Rattenpankreas. Dissertation 1-81. Ernst-Moritz-Arndt-Universität-Greifswald
Kohnert K. D., Ziegler B., Falt K., Odselius R., Ziegler M., and Falkmer S. (1987). Biochemical, immunohistochemical and ultrastructural studies of the alteration of pancreatic beta cells resulting from the combined effects of complete Freund’s adjuvant and non-diabetogenic doses of streptozotocin. Exp. Clin. Endocrinol. 89, 259–268
Lucke S., Radloff E., Laube R., and Hahn H. J. (1991). Morphology of the endocrine pancreas in cyclosporine-treated glucose-intolerant Wistar rats. Anat. Anz. 172, 351–358
Kohnert K. D., Falt K., Witt S., Ziegler B., and Ziegler M. (1988). Identification of monoclonal antibodies to pancreatic islet cells by immunoperoxidase staining. Acta Histochem. 83, 159–165
Augstein P., Braun B., Ziegler B., Woltanski K. P., and Ziegler M. (1992). Characterization of two porcine proinsulin reactive monoclonal antibodies by immunostaining of beta-cells in pancreatic sections of different species. Acta Histochem. 93, 433–440
Acknowledgement
The authors are grateful to Silke Lucke (PhD) and Klaus-Dieter Kohnert (PhD, MD) for their advice and for sharing their expertise. Our special thanks go to Peter Heinke (MSc.) for his excellent and competent support for mathematical and statistical evaluations. We acknowledge the contributions of Dieter Schröder (PhD) and Sabine Berg (MSc.). We thank Dr. Klaus-Dieter Kohnert for a critical review of the manuscript, Mrs. Cordula Rudolph and Mrs. Marlies Behm for excellent technical assistance.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Augstein, P., Salzsieder, E. (2009). Morphology of Pancreatic Islets: A Time Course of Pre-diabetes in Zucker Fatty Rats. In: Stocker, C. (eds) Type 2 Diabetes. Methods in Molecular Biology, vol 560. Humana Press. https://doi.org/10.1007/978-1-59745-448-3_12
Download citation
DOI: https://doi.org/10.1007/978-1-59745-448-3_12
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-934115-15-2
Online ISBN: 978-1-59745-448-3
eBook Packages: Springer Protocols